click enter text
report financi result thursday market
close revenu ep came ahead consensu modest
boost covid maintain prior financi guidanc
quarter otherwis quiet
rais forecast modestli also price target bodi
report full analysi
inform see slide initi peer
addit context compar cover larg cap
biotech us/eu pharma name see slide initi larg cap
add exist us/eu pharma name cover
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
thursday close
report result ahead consensu revenu ep
overal impress report solid larg quiet quarter close thursday partial boost
covid compani reiter confid portfolio growth product biosimilar
felt comfort reaffirm guidanc line major cover compani
done earn season confer call analyst question broad base
potenti neg impact amgn portfolio remaind given
compani higher exposur physician-administ product interest amgn initi combat
covid antibodi collabor adapt separ otezla question kra
upcom monotherapi readout nsclc durabl respons remain key question
potenti opportunist busi develop manag describ keen interest
oncolog immunolog similar compani larg cap pharma biotech coverag
amgn long-term growth prospect modestli better averag model valuat
averag price-to-earnings multipl basi current level stock feel fairli valu us
posit catalyst anticip mainli form pipelin readout fact posit
also one major risk appeal court rule enbrel markedli skew downsid
market assum prevail enbrel compani largest product
annual sale
rate peer perform inform see recent launch materi slide initi
peer perform
addit context compar cover larg cap biotech us/eu pharma
name see slide initi larg cap biotech add exist us/eu pharma name cover
revenu report sale vs estim consensu
ep report non-gaap ep vs estim consensu
enbrel sale vs consensu neulasta sale vs
consensu prolia sale vs consensu xgeva sale
vs consensu repatha sale vs consensu
aimovig sale vs consensu otezla sale vs
revenu maintain prior level
page
ep maintain prior level
revenu increas ep
revenu estim increas around averag ep estim increas
averag
ep compound-annual-growth-rate ep compound-annual-growth-rate increas slightli vs prior repres
peer averag growth peer average compound-annual-growth-rate
price target increas target repres increas multipl new
manag disrupt quit well healthi balanc sheet attract portfolio
product adapt organ
complet integr astella partnership japan note product collabor bgne
china full year expect total oper expens grow high singl digit percentag rang
yoy cog benefit lower manufactur expens partial off-set mileston expect margin
gener in-lin expect otezla spend drive increas sg lower
interest incom cash balanc loss secur drove declin oie expect start
recogn share bgne profit/loss continu opportunist share repurchas
low end rang
 oper margin tick slightli expect evolv year
expect remain industry-lead oper margin give guidanc beyond
 growth acceler covid environ affect stanc bd wont comment
beyond extern innov remain import capit alloc prioriti
 see typic destock saw inventori build quarter across
market exposur physician-administ product minim impact earli script fill
 want go target oncolog immunolog expect bolt-on
dont know area keen interest find asset
price make sens return sharehold
page
 see greatest opportun right approach perspect platform
greatest interest
 polit rhetor around pharma industri chang due covid pandem govern
innov academia collabor unpreced speed scale view
posit note convers around drug price go away though
four prioriti protect staff ensur continu suppli medic work antibodi
support commun market condit improv point
workforc return work essenti manufactur activ remain on-going signific
disrupt suppli chain perspect dont expect disrupt pivot clinic trial fulli
enrol reiter read-out year program like bite continu progress flag otezla
potenti benefici treat respiratori distress sever covid patient investig
question disrupt covid strong perform expect
recoveri led reaffirm guidanc vari impact covid portfolio note
delay diagnosi treatment decreas new patient start patient visit physician less note
patient refil script earli drive posit impact product like prolia neg
impact due less in-offic visit note product like otezla could benefit
 could give color differenti antibodi approach well timelin
tri combin immuno-profil capabl platform note partnership
realli focus develop highest qualiti candid activ lab also bring
manufactur capabl tabl well ensur broad access
 manag payor shift unemploy overal medicaid busi current
reimburs commerci hard predict rate patient switch medicaid
due furlough measur like cobra impact could actual delay late
 telemedicin impact busi integr telemedicin differ greatli across therapeut
area note dermatolog neurolog pretti seamless transit product like even
neg impact use post-fractur amen telemedicin
 product affect reduct in-offic visit flag prolia call
note yet see impact yet bone health bucket heavili affect view
nephrolog hold well patient requir dialysi life oncolog nearli much
bone
 chang infrastructur model thing return normal cant realli predict
point chang industri think industri need adapt busi continu plan among
 addit comment around covid trial otezla think potenti benefit patient across
diseas spectrum guid principl need rigor studi provid answer
page
current covid environ otezla benefit amen telemedicin also requir
lab monitor expect small benefit net sell price enbrel sale
 describ event sandoz win appeal enbrel ip challeng wont go detail
remain confid
 benefit otezla covid sustain trend continu monitor trend talk
custom believ buffer protect otezla given conveni afford also see benefit
expand footprint primari care set
dialysi clinic see signific neg impact covid parsabiv use major
calcimimet patient independ dialysi provid see continu share gain
prolia demand growth grew in-lin previou year began see demand step-down toward end
march demand begin stabil howev updat look novel
approach includ altern site mobil nurs retail pharmaci even share japan similar
anabol therapi us demand driven physician gain experi
drug note year therapi help facilit switch prolia
amgevita humira biosimilar europ three quarter remain kanjinti exit quarter
share note expand util clinic hospit
 commerci outlook biosimilar remicad biosimilar attribut
success reput reliabl biolog manufactur integr commerci busi
also appli patient servic biosimilar plan launch avsola year
 earli experi covid biosimilar seen steepen uptak curv
assess potenti impact chang total number cycl product
 market becom crowd view long-term price eros
experi make biolog scale effici way note price eros eu like steeper
us market develop
product like xgeva like neg impact neulasta onpro biosimilar may benefit
kyproli growth driven expand share mm neulasta benefit barda order
note onpro maintain major share howev share
page
volum growth yoy nbrx grew steadili quarter part contract led step-down
net sell price expect stabl rest
aimovig remain market leader among cgrp share addit formulari
access cover live paid prescript share off-set lower net sell price increas co-pay
 give color around aimovig perform pleas aimovig share perform
paid prescript rate go forward theyr count lock addit patient volum
physician tend continu use older oral migrain drug tri drive switch
continu expect respons data monotherapi lung expect otezla
advanc data within come week paus clinic trial dont believ site safe
treat monitor patient note circumv issu remot monitor altern
site home deliveri product affect product includ hle bite hand
oncolog trial file xgeva china skeletal-rel event note continu transfer
respons partner bgne work intent identifi optim therapeut
antibodi close collabor regulatori agenc note expect multipl
gener covid antibodi look produc best otezla enter platform trial
covid come week
 think monotherapi relev tumor type
continu enrol monotherapi cohort evalu whether path forward without
combo therapi provid updat appendic pancreat cancer among other
combo trial expect initi data either later year earli next year
 could share perspect view efficaci bar nsclc monotherapi
expect data want see robust respons rate durabl patient
 phase trial compar docetaxel larg docetaxel
soc set around world regul agre sampl size power overal
 question develop primarili develop combo partner
pipelin asset ultim think theyll need treat patient monotherapi standard
 optimist durat respons durabl remain key question
regard combo bit earli pick favorit base underli biolog
page
 level excit around mutein program expect data cours year
mayb earli next year due paus trial investig hesit suppress t-
cell current environ
page
exhibit show compani report actual result vs estim consensu
exhibit amgen result vs wr estim consensu
exhibit summar financi guidanc vs estim
exhibit amgen guidanc vs wr estim old new
page
exhibit captur chang forecast
exhibit chang wr model
page
exhibit show incom statement product revenu summari balanc sheet/cash flow
page
incom statement oper incom expens outstand margin total profit profit profit incom growth oper
page
exhibit wr balanc sheet cash flow statement
page
flow statement incom intang chang oper asset flow oper activ busi net cash acquisit properti flow invest activ lt debt leas treasuri flow financ activ increas decreas cash sheet cash equival st properti plant goodwil current term non-curr comprehens sharehold liabil sharehold
